Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows
Executive Summary
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
You may also be interested in...
As Chloroquine Demand Surges, Bayer Looks To Emergency Use Authorization To Enter US Market
Unlike diagnostics, EUAs for drugs are rare and the fact that there already are FDA-approved competitors for Bayer’s chloroquine phosphate product may make the decision more complicated.
COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial
First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.